Neladalkib Shows Promise for Heavily Pre-treated ALK-Positive Lung Cancer Patients
Table of Contents
A new treatment option may be on the horizon for patients battling advanced ALK-positive non-small cell lung cancer (NSCLC), as initial data from the ALKOVE-1 trial demonstrate significant efficacy and a manageable safety profile for the investigational drug neladalkib (NVL-655).The findings, released November 17, 2025, offer hope for individuals who have exhausted existing therapies, including multiple generations of tyrosine kinase inhibitors (TKIs).
Addressing a Significant Unmet Need in Lung Cancer Treatment
ALK fusions are present in roughly 1% to 4% of lung cancers, most frequently in adenocarcinomas. While less common than other genetic drivers of the disease, these alterations pose a ample challenge for patients, often requiring a complex treatment journey. Current ALK inhibitors can loose effectiveness as tumors develop resistance, necessitating the search for next-generation therapies.
Neladalkib: A Novel Approach to ALK Inhibition
Neladalkib is designed to overcome limitations of existing ALK-targeted therapies. This next-generation inhibitor is engineered to maintain efficacy even as tumors become resistant to first-, second-, and third-generation ALK inhibitors. Notably, it has demonstrated activity against challenging mutations like G1202R, a common mechanism of resistance.
The drug’s unique design also allows it to penetrate the blood-brain barrier while specifically targeting ALK, avoiding activity against the related TRK receptor family. this selective approach aims to minimize the central nervous system (CNS) toxicities sometimes associated with dual ALK/TRK inhibitors, possibly improving patients’ quality of life.
ALKOVE-1 Trial: Key Findings and Patient Population
The ALKOVE-1 study is a global,open-label phase 1/2 trial evaluating neladalkib in patients with advanced ALK-positive NSCLC who have previously received ALK TKIs. Phase 1 established a recommended phase 2 dose of 150 mg once daily. Phase 2 involved a cohort of 253 heavily pre-treated patients, with a median of three prior lines of therapy. A substantial proportion – 78% – had received two or more prior ALK TKIs,and many had previously been treated with lorlatinib. The study population also included patients with chemotherapy exposure, baseline brain metastases, and treatment-emergent ALK mutations.
Promising Efficacy Across Multiple Subgroups
In the pivotal cohort, neladalkib achieved an objective response rate (ORR) of 31% (95% CI: 26, 37). Responses where notably durable, with an estimated 64% of responders maintaining benefit for at least 12 months and 53% for at least 18 months.
Outcomes were even more encouraging in patients who had not previously received lorlatinib, demonstrating a 46% ORR and an estimated 80% 12-month durability. Neladalkib also exhibited significant intracranial activity, with an intracranial ORR of 32% among patients with measurable brain metastases.
